Pacylex CEO reveals Zelenirstat phase one results

Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.

Related Keywords

United States ,Michael Weickert ,Pacylex Pharmaceuticals ,World Orphan Drug Congress United States ,Stable Disease ,Myeloid Leukemia ,Acute Myeloid Leukemia ,Fast Track ,New Drug ,Drink Administration ,Pacylex Pharmaceutical ,Clinical Development ,Ingredients ,Atient Centricity ,Pis Active Pharmaceutical Ingredients ,Hasei Ii ,Gastrointestinal ,Lymphoma ,Clinical Trials ,Leukemia ,Research ,